Recipharm to make 3-API drug for Israel’s RedHill

By Fiona BARRY

- Last updated on GMT

RedHill's drug candidate comprises two antibiotics and a proton pump inhibitor
RedHill's drug candidate comprises two antibiotics and a proton pump inhibitor
Swedish CDMO Recipharm will contract manufacture a three-drug combination antibiotic for emerging Israeli biopharma RedHill.

The contract development and manufacturing organisation (CDMO) will produce RHB-105 for clinical trials and later for commercial supply.

The drug candidate contains two antibiotics, amoxicillian and rifabutin, as well as the proton pump inhibitor omeprazole in one oral dose. It targets Helicobacter pylori ​(H. pylori​) bacterial infection, a market the companies say is worth $4.8bn (€4.2bn).

RHB-105 was successful in a Phase III study which ended in June.

Three site manufacture

Recipharm said RedHill’s order is a complicated manufacturing job and the first to involve three Recipharm sites.

FDA-approved facilities in Fontaine and Pessac, France will produce omeprazole pellets and a plant in Strängnäs, Sweden will encapsulate and package the final product. Recipharm will invest 13m Swedish Krona ($1.6m) in upgrading manufacturing at the Swedish site and will apply for FDA registration.

Erik Haeffler, VP, manufacturing services, Recipharm said spreading production across three sites is an “integrated solution to solve a complex manufacturing project.​”

The companies said they expect RHB-105 to be launched in the US before the EU.

RedHill’s pipeline also includes an oral combination therapy in Phase III for Chrohn’s disease, a Phase III ondansetron pill for chemotherapy nausea, a bowel preparation licensed to Salix, and several Phase I and II candidates.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars